Adial pharmaceuticals, inc. (ADIL)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Dec'17
ASSETS
Current Assets:
Cash and cash equivalents

4,951

6,777

8,529

10,254

11,394

3,869

4,816

150

18

Prepaid research and development

743

536

460

271

379

505

-

-

-

Prepaid expenses and other current assets

240

359

510

155

279

317

428

30

9

Total Current Assets

5,935

7,673

9,500

10,680

12,053

4,692

5,245

180

27

Intangible assets, net

6

6

6

6

6

6

6

7

7

Total Other Assets

6

6

6

6

6

6

6

7

7

Total Assets

5,941

7,679

9,506

10,687

12,059

4,699

5,252

187

34

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable

196

190

776

626

329

-

184

481

342

Accounts payable

-

-

-

-

-

99

-

-

-

Accrued expenses

193

348

-

-

-

158

-

-

-

Senior note, net of discount of $186,397 at September 30, 2018

-

-

-

-

-

-

138

28

-

Senior secured notes (related parties $470,000 at June 30, 2018)

-

-

-

-

-

-

-

510

-

Senior secured bridge note payable, net of discount of $23,363 at December 31, 2017

-

-

-

-

-

-

0

225

351

Subordinated notes payable - related parties, net of discount $11,685 at December 31, 2017

-

-

-

-

-

-

0

0

103

Convertible notes payable, net of discount of $687 at December 31, 2017

-

-

-

-

-

-

0

234

234

Derivative liability

-

-

-

-

-

-

0

0

0

Total Current Liabilities

389

539

776

626

329

257

322

1,480

1,032

Commitments and contingencies

-

-

-

-

-

-

0

0

-

Shareholders' Equity
Preferred Stock, 5,000,000 shares authorized with a par value of $0.001 per share, 0 shares outstanding at March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

-

Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 10,629,603 and 10,368,352 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

10

10

10

10

10

6

6

3

3

Additional paid in capital

28,444

27,757

27,287

26,903

26,438

16,469

15,689

1,278

-596

Accumulated deficit

-22,903

-20,626

-18,568

-16,852

-14,718

-12,035

-10,766

-2,575

-403

Total Shareholders' Equity

5,551

7,140

8,729

10,060

11,730

4,441

4,929

-1,293

-997

Total Liabilities and Shareholders' Equity

5,941

7,679

9,506

10,687

12,059

4,699

5,252

187

34